Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.

Marta Larrayoz 1 , Maria J Garcia-Barchino 1 , Jon Celay 1 , Amaia Etxebeste 1 , Maddalen Jimenez 1 , Cristina Perez 1 , Raquel Ordoñez 1 , Cesar Cobaleda 2 , Cirino Botta 1 3 , Vicente Fresquet 1 , Sergio Roa 1 , Ibai Goicoechea 1 , Catarina Maia 1 , Miren Lasaga 1 , Marta Chesi 4 , P Leif Bergsagel 4 , Maria J Larrayoz 1 , Maria J Calasanz 1 , Elena Campos-Sanchez 2 , Jorge Martinez-Cano 2 , Carlos Panizo 5 , Paula Rodriguez-Otero 5 , Silvestre Vicent 6 , Giovanna Roncador 7 , Patricia Gonzalez 7 , Satoru Takahashi 8 , Samuel G Katz 9 , Loren D Walensky 10 , Shannon M Ruppert 11 , Elisabeth A Lasater 12 , Maria Amann 13 , Teresa Lozano 14 , Diana Llopiz 14 , Pablo Sarobe 14 , Juan J Lasarte 14 , Nuria Planell 15 , David Gomez-Cabrero 15 16 , Olga Kudryashova 17 , Anna Kurilovich 17 , Maria V Revuelta 18 , Leandro Cerchietti 18 , Xabier Agirre 1 , Jesus San Miguel 1 5 , Bruno Paiva 1 5 , Felipe Prosper 1 5 , Jose A Martinez-Climent 19